Introduction of New Vaccines in the Healthcare System

The Vaccine Book

Volumn , Issue , 2003, Pages 391-410

  Mulholland, Edward Kim ^a   Bjorvatn, Bjarne ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883024184     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012107258-2/50029-9     Document Type: Chapter

References (30)

1. Black S., Lieu T.A., Ray G.T., et al. Assessing the costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente. Vaccine 2001, 19(Suppl.):S83-S86.
2. World Health Organization Expanded Programme on Immunization EPI Information System: Global Summary. Document WHO/EPI/CEIS/96.07 1996, 196.
3. Ryder R.W., Whittle H.C., Sanneh A.B., et al. Persistent hepatitis b infection and hepatoma in the Gambia, Africa. A case-control study of 140 adults and their 603 family contacts. Am. J. Epidemiol. 1992, 136:1122-1131.
4. Mulholland E.K. Magnitude of the problem of childhood pneumonia in developing countries. Lancet 1999, 354:590-592.
5. Black S.B., Shinefield H., Firemnan B., et al. Efficacy, Safety and Immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 2000, 19:187-195.
6. Eskola J., Kilpi T., Palmu A., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. New England J. Med. 2001, 344(6):403-409.
7. Levine M.M., Levine O.S. Influence of disease burden, public perception, and other factors on new vaccine development, implementation and continued use. Lancet 1997, 350:1386-1392.
8. Jafari H.S., Adams W.G., Robinson K.A., Plikaytis B.D., Wenger J.D. Efficacy of Haemophilus influenzae type b conjugate vaccines and persistence of disease in disadvantaged populations. The Haemophilus influenzae Study Group. Am. J. Public Health 1999, 89:364-368.
9. Joensuu J., Kosenniemi E., Pang X.-L., Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997, 350:1205-1209.
10. Clemens J., Brenner R., Rao M., Tafari N., Lowe C. Evaluating new vaccines for developing countries. J. Am. Med. Assoc. 1996, 275:390-397.
11. Reingold A.L., Broome C.V., Hightower A.W., Ajello G.W., Bolan G.A., Adamsbaum C., Jones E.E., Phillips C., Tiendrebeogo H., Yada A. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985, 2(8447):114-118.
12. Mulholland E.K. Measles and pertussis in developing countries with good vaccine coverage. Lancet 1995, 345:305-307.
13. Global Programme for Vaccines and Immunization The WHO position paper on rubella vaccines. Weekly Epidemiol. Record 2000, 75:161-169.
14. Robertson S.E., Cutts F.T., Samuel R., Diaz-Ortega J.-L. Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 2: Vaccination against rubella. Bull. WHO 1997, 75:69-80.
15. Mbelle N., Huebner R.E., Wasas A., et al. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J. Infect. Dis. 1999, 180:1171-1176.
16. Feudtner C., Marcuse E.K. Ethics and immunization policy: Promoting dialogue to sustain consensus. Pediatrics 2001, 107:1158-1164.
17. Poland G.A., Jacobson R.M. Understanding those who do not understand: A brief review of the anti-vaccine movement. Vaccine 2001, 19:2440-2445.
18. King S. Vaccination policies: Individual rights vs community health. We can't afford to be half hearted about vaccination programmes. Br. Med. J. 1999, 319:1448-1449.
19. Gangarosa E.J., Galazka A.M., Wolfe C.R., et al. Impact of anti-vaccine movements on pertussis control: The untold story. Lancet 1998, 351:1019-1021.
20. Global Programme for Vaccines and Immunization The WHO position paper on pertussis vaccines. Weekly Epidemiol. Record 1999, 74:137-143.
21. Rennels M.B., Parashar U.D., Holman R.C., et al. Lack of an apparent association between intussusception and wild or vaccine rotavirus infection. Pediatr. Infect. Dis. J. 1998, 17:924-925.
22. Murphy T.V., Gargiullo P.M., Massoudi M.S., et al. Intussusception among infants given an oral rotavirus vaccine. New England J. Med. 2001, 344:564-572.
23. Guo J.Z., Ma X.Y., Zhou Q.H. Results of air pressure enema reduction of intussusception: 6,396 cases in 13 years. J. Pediatr. Surg. 1986, 21:1201-1203.
24. European Commission COST/STD Initiative Report of the Expert Panel V: Harmonization of European Vaccination Programmes. Vaccine 1996, 14:611-623.
25. Miller M.A., Flanders W.D. A model to estimate the probability of hepatitis B- and Haemophilus influenzae type b-vaccine uptake into national vaccination programs. Vaccine 2000, 18:2223-2230.
26. Sinha A., Sazawal S., Kumar R., Sood S., Reddaiah V.P., Singh B., Rao M., Naficy A., Clemens J.D., Bhan M.K. Typhoid fever in children aged less than 5 years. Lancet 1999, 354:734-737.
27. Lin F.Y.C., Ho V.A., Kheim H.B., et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. New England J. Med. 2001, 344:1263-1269.
28. Batson A. Sustainable introduction of affordable new vaccines: The targeting strategy. Vaccine 1998, 16(Suppl.):S93-S98.
29. Mahoney R.T., Ramachandran S., Xu Z. The introduction of new vaccines into developing countries II. Vaccine financing. Vaccine 2000, 24:2625-2635.
30. Hausdorff W.P. Prospects for the use of new vaccines in developing countries: Cost is not the only impediment. Vaccine 1996, 14:1179-1186.